These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29503151)

  • 1. Management-Based Structured Reporting of Posttreatment Glioma Response With the Brain Tumor Reporting and Data System.
    Weinberg BD; Gore A; Shu HG; Olson JJ; Duszak R; Voloschin AD; Hoch MJ
    J Am Coll Radiol; 2018 May; 15(5):767-771. PubMed ID: 29503151
    [No Abstract]   [Full Text] [Related]  

  • 2. Radiology: criteria for determining response to treatment and recurrence of high-grade gliomas.
    Lucas J; Zada G
    Neurosurg Clin N Am; 2012 Apr; 23(2):269-76, viii. PubMed ID: 22440870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.
    Boxerman JL; Ellingson BM; Jeyapalan S; Elinzano H; Harris RJ; Rogg JM; Pope WB; Safran H
    Am J Clin Oncol; 2017 Jun; 40(3):228-234. PubMed ID: 25436828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Computed tomographic features of cerebral malignant glioma following treatment and regrowth. Growth patterns of recurrent tumors].
    Sato I; Tanaka R; Takeda N; Suzuki Y; Hondo H
    Neurol Med Chir (Tokyo); 1988 Nov; 28(11):1073-80. PubMed ID: 2466210
    [No Abstract]   [Full Text] [Related]  

  • 5. Imaging of intratumoral heterogeneity in high-grade glioma.
    Hu LS; Hawkins-Daarud A; Wang L; Li J; Swanson KR
    Cancer Lett; 2020 May; 477():97-106. PubMed ID: 32112907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in Magnetic Resonance and Positron Emission Tomography Imaging: Assessing Response in the Treatment of Low-Grade Glioma.
    Kim MM; Lawrence TS; Cao Y
    Semin Radiat Oncol; 2015 Jul; 25(3):172-80. PubMed ID: 26050587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCL12 and CXCR4 as predictive biomarkers of glioma recurrence pattern after total resection.
    Tang W; Wang X; Chen Y; Zhang J; Chen Y; Lin Z
    Pathol Biol (Paris); 2015 Sep; 63(4-5):190-8. PubMed ID: 26277915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striking a Chord? Not a Typical Low-Grade Glioma.
    McDermott DM; Singh SA
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):518-519. PubMed ID: 32976779
    [No Abstract]   [Full Text] [Related]  

  • 9. Posttreatment evaluation of central nervous system gliomas.
    Shiroishi MS; Booker MT; Agarwal M; Jain N; Naghi I; Lerner A; Law M
    Magn Reson Imaging Clin N Am; 2013 May; 21(2):241-68. PubMed ID: 23642552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic deactivation of low-grade glioma during chemotherapy.
    Roelcke U; Wyss M; Bärtschi E; Hofer S
    J Neurol; 2007 May; 254(5):668-9. PubMed ID: 17410330
    [No Abstract]   [Full Text] [Related]  

  • 11. Low-grade Glioma, High Stakes Controversy-When and How to Treat in the Molecular Era?
    Tom MC; Murphy ES
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):516-517. PubMed ID: 29893268
    [No Abstract]   [Full Text] [Related]  

  • 12. Local control of gliomas: the next best step--a good step?
    Westphal M; Giese A
    Front Radiat Ther Oncol; 1999; 33():214-26. PubMed ID: 10549491
    [No Abstract]   [Full Text] [Related]  

  • 13. Brain stem gliomas: therapeutic options at time of recurrence.
    Rekate HL
    Pediatr Neurosurg; 1996 Oct; 25(4):220. PubMed ID: 9293549
    [No Abstract]   [Full Text] [Related]  

  • 14. 11C-MET PET/CT and advanced MRI in the evaluation of tumor recurrence in high-grade gliomas.
    D'Souza MM; Sharma R; Jaimini A; Panwar P; Saw S; Kaur P; Mondal A; Mishra A; Tripathi RP
    Clin Nucl Med; 2014 Sep; 39(9):791-8. PubMed ID: 25036022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scintigraphic assessment of recurrent glioma with focus on proliferation.
    Alexiou GA; Tsiouris S; Polyzoidis KS; Kyritsis AP; Fotopoulos AD
    Nucl Med Commun; 2008 Sep; 29(9):840-1. PubMed ID: 18677216
    [No Abstract]   [Full Text] [Related]  

  • 16. Diagnostic validity and reliability of BT-RADS in the management of recurrent high-grade glioma.
    Ebaid NY; Ahmed RN; Assy MM; Amin MI; Alaa Eldin AM; Alsowey AM; Abdelhay RM
    J Neuroradiol; 2024 Jun; 51(4):101190. PubMed ID: 38492800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiosensitization of high-grade gliomas through induced hyperthermia: Review of clinical experience and the potential role of MR-guided focused ultrasound.
    Schneider CS; Woodworth GF; Vujaskovic Z; Mishra MV
    Radiother Oncol; 2020 Jan; 142():43-51. PubMed ID: 31431370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular imaging and advanced MRI findings following immunotherapy in patients with brain tumors.
    Galldiks N; Lohmann P; Werner JM; Ceccon G; Fink GR; Langen KJ
    Expert Rev Anticancer Ther; 2020 Jan; 20(1):9-15. PubMed ID: 31842635
    [No Abstract]   [Full Text] [Related]  

  • 19. Posttreatment high-grade glioma: usefulness of peak height position with semiquantitative MR perfusion histogram analysis in an entire contrast-enhanced lesion for predicting volume fraction of recurrence.
    Kim HS; Kim JH; Kim SH; Cho KG; Kim SY
    Radiology; 2010 Sep; 256(3):906-15. PubMed ID: 20634429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma.
    Vos MJ; Hoekstra OS; Barkhof F; Berkhof J; Heimans JJ; van Groeningen CJ; Vandertop WP; Slotman BJ; Postma TJ
    J Clin Oncol; 2003 Oct; 21(19):3559-65. PubMed ID: 12913097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.